Back to Search
DAVID MILTON, MD
MD
Diagnostic Radiology Physician
NPI: 1356367130Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
PMID 17577220·Cancer·2007
3-trial
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
PMID 16878326·Cancer·2006
3-trial
Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
PMID 15558327·Support Care Cancer·2005
5-case
Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer.
PMID 15988685·Semin Oncol·2005
6-review
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
PMID 19433684·J Clin Oncol·2009
3-trial
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
PMID 19047285·J Clin Oncol·2009
3-trial
Development of a new isotopically labeled internal standard for ergosterol measurement by GC/MS.
PMID 19657536·J Environ Monit·2009
8-other
Type VI secretion modulates quorum sensing and stress response in Vibrio anguillarum.
PMID 19624706·Environ Microbiol·2009
8-other
Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial.
PMID 19622464·J Chemother·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 534 BILTMORE AVE
ASHEVILLE, NC 28801 - Phone
- (828) 213-0594
Quick Facts
- NPI
- 1356367130
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile